Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization

Molecular Immunology

Volumn 48, Issue 4, 2011, Pages 706-713

  Yue, Yan ^a   Gui, Jun ^b   Xu, Wei ^b   Xiong Sidong, S ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

CCL2; CVB3; Gene therapy; Inflammation; Myocarditis

Indexed keywords

AMINO ACID DERIVATIVE; CD4 ANTIGEN; GAMMA INTERFERON; MONOCYTE CHEMOTACTIC PROTEIN 1;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CHEMOTAXIS; CONTROLLED STUDY; COXSACKIE VIRUS B3; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ANTAGONISM; GENE THERAPY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLARIZATION; PRIORITY JOURNAL; SURVIVAL RATE; TH1 CELL; TH2 CELL; VIRUS MYOCARDITIS; WEIGHT REDUCTION;

ANIMALS; CELL MOVEMENT; CELL POLARITY; CHEMOKINE CCL2; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; GENE THERAPY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MUTANT PROTEINS; MYOCARDITIS; MYOCARDIUM; PLASMIDS; SPLEEN; TH1 CELLS; UP-REGULATION;

COXSACKIEVIRUS; MUS;

EID: 78650613866     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.11.018     Document Type: Article

References (37)

1. Buraczynska M., Bednarek-Skublewska A., Buraczynska K., Ksiazek A. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients. Cytokine 2008, 44:361-365.
2. Cai S.H., Tan Y., Ren X.D., Li X.H., Cai S.X., Du J. Loss of C-terminal alpha-helix decreased SDF-1alpha-mediated signaling and chemotaxis without influencing CXCR4 internalization. Acta Pharmacol. Sin. 2004, 25:152-160.
3. Cook D.N., Beck M.A., Coffman T.M., Kirby S.L., Sheridan J.F., Pragnell I.B., Smithies O. Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995, 269:1583-1585.
4. Dessing M.C., van der Sluijs K.F., Florquin S., van der Poll T. Monocyte chemoattractant protein 1 contributes to an adequate immune response in influenza pneumonia. Clin. Immunol. 2007, 125:328-336.
5. Dey R., Majumder N., Bhattacharyya Majumdar S., Bhattacharjee S., Banerjee S., Roy S., Majumdar S. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice. Scand. J. Immunol. 2007, 66:671-683.
6. Egashira K., Koyanagi M., Kitamoto S., Ni W., Kataoka C., Morishita R., Kaneda Y., Akiyama C., Nishida K.I., Sueishi K., Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. FASEB J. 2000, 14:1974-1978.
7. Egashira K., Nakano K., Ohtani K., Funakoshi K., Zhao G., Ihara Y., Koga J., Kimura S., Tominaga R., Sunagawa K. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2563-2568.
8. Fairweather D., Rose N.R. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 2007, 41:118-122.
9. Fleury S., Li J., Simeoni E., Fiorini E., von Segesser L.K., Kappenberger L., Vassalli G. Gene transfer of RANTES and MCP-1 chemokine antagonists prolongs cardiac allograft survival. Gene Ther. 2006, 13:1104-1109.
10. Göser S., Ottl R., Brodner A., Dengler T.J., Torzewski J., Egashira K., Rose N.R., Katus H.A., Kaya Z. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 2005, 112:3400-3407.
11. Grabie N., Delfs M.W., Westrich J.R., Love V.A., Stavrakis G., Ahmad F., Seidman C.E., Seidman J.G., Lichtman A.H. IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. J. Clin. Invest. 2003, 111:671-680.
12. Henke A., Huber S., Stelzner A., Whitton J.L. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 1995, 69:6720-6728.
13. Henke A., Jarasch N., Wutzler P. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis. Exp. Rev. Vaccines 2008, 7:1557-1567.
14. Hokeness K.L., Kuziel W.A., Biron C.A., Salazar-Mather T.P. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J. Immunol. 2005, 174:1549-1556.
15. Huang D.R., Wang J., Kivisakk P., Rollins B.J., Ransohoff R.M. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 2001, 193:713-726.
16. Huber S.A. Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d. Med. Microbiol. Immunol. 2005, 194:121-127.
17. Huber S.A., Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J. Virol. 1994, 68:5126-5132.
18. Ip W.K., Wong C.K., Lam C.W. Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathways. Clin. Exp. Immunol. 2006, 145:162-172.
19. Jiang Z., Xu W., Li K., Yue Y., Xu L., Ye F., Xiong S. Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer. J. Gene Med. 2008, 10:918-929.
20. Karpus W.J., Kennedy K.J. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukoc. Biol. 1997, 62:681-687.
21. Kishimoto C., Kawamata H., Sakai S., Shinohara H., Ochiai H. Enhanced production of macrophage inflammatory protein 2 (MIP-2) by in vitro and in vivo infections with encephalomyocarditis virus and modulation of myocarditis with an antibody against MIP-2. J. Virol. 2001, 75:1294-1300.
22. Kitamoto S., Egashira K. Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases. Exp. Rev. Cardiovasc. Ther. 2003, 1:393-400.
23. Li K., Xu W., Guo Q., Jiang Z., Wang P., Yue Y., Xiong S. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ. Res. 2009, 105:353-364.
24. Luther S.A., Cyster J.G. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2001, 2:102-107.
25. Marino A.P., Silva A.A., Santos P.V., Pinto L.M., Gazinelli R.T., Teixeira M.M., Lannes-Vieira J. CC-chemokine receptors: a potential therapeutic target for Trypanosoma cruzi-elicited myocarditis. Mem. Inst. Oswaldo. Cruz. 2005, 100(Suppl. 1):93-96.
26. Nakajima H., Kobayashi M., Pollard R.B., Suzuki F. Monocyte chemoattractant protein-1 enhances HSV-induced encephalomyelitis by stimulating Th2 responses. J. Leukoc. Biol. 2001, 70:374-380.
27. Paavola C.D., Hemmerich S., Grunberger D., Polsky I., Bloom A., Freedman R., Mulkins M., Bhakta S., McCarley D., Wiesent L., Wong B., Jarnagin K., Handel T.M. Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J. Biol. Chem. 1998, 273:33157-33165.
28. Poffenberger M.C., Straka N., El Warry N., Fang D., Shanina I., Horwitz M.S. Lack of IL-6 during coxsackievirus infection heightens the early immune response resulting in increased severity of chronic autoimmune myocarditis. PLoS One 2009, 4:e6207.
29. Rollins B.J. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol. Med. Today 1996, 2:198-204.
30. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1950-1959.
31. Shen Y., Xu W., Chu Y.W., Wang Y., Liu Q.S., Xiong S.D. Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J. Virol. 2004, 78:12548-12556.
32. Szekanecz Z., Koch A.E. Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Curr. Opin. Pharmacol. 2004, 4:423-428.
33. Tam P.E. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 2006, 19:133-146.
34. Thompson W.L., Karpus W.J., Van Eldik L.J. MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J. Neuroinflamm. 2008, 5:35.
35. Tsuruta S., Nakamuta M., Enjoji M., Kotoh K., Hiasa K., Egashira K., Nawata H. Anti-monocyte chemoattractant protein-1 gene therapy prevents dimethylnitrosamine-induced hepatic fibrosis in rats. Int. J. Mol. Med. 2004, 14:837-842.
36. Yuan J., Liu Z., Lim T., Zhang H., He J., Walker E., Shier C., Wang Y., Su Y., Sall A., McManus B., Yang D. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ. Res. 2009, 104:628-638.
37. Zhang Y., Rollins B.J. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol. Cell. Biol. 1995, 15:4851-4855.